12/4
07:30 am
plrx
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
High
Report
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
12/1
08:30 am
plrx
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference
Low
Report
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference
11/16
01:10 am
plrx
Pliant Therapeutics (NASDAQ:PLRX) was upgraded by analysts at
Wall Stree
Low
Report
Pliant Therapeutics (NASDAQ:PLRX) was upgraded by analysts at
Wall Stree
11/7
02:22 pm
plrx
Pliant Therapeutics (NASDAQ:PLRX) had its price target lowered by analysts at Royal Bank Of Canada from $3.00 to $2.00. They now have a "sector perform" rating on the stock.
Medium
Report
Pliant Therapeutics (NASDAQ:PLRX) had its price target lowered by analysts at Royal Bank Of Canada from $3.00 to $2.00. They now have a "sector perform" rating on the stock.
11/6
04:05 pm
plrx
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Medium
Report
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
10/10
08:06 am
plrx
Pliant Therapeutics (NASDAQ:PLRX) had its "underweight" rating reaffirmed by analysts at JPMorgan Chase & Co..
Low
Report
Pliant Therapeutics (NASDAQ:PLRX) had its "underweight" rating reaffirmed by analysts at JPMorgan Chase & Co..